A medical device for administering a liquid containing humoral factors produced by cells to a target site.

A medical device with a reservoir and clamping portion for gradual cell suspension delivery addresses the burden of frequent cell administration by enabling continuous and replenishable humoral factor release.

JP7845880B2Active Publication Date: 2026-04-14TERUMO KK
View PDF 6 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
TERUMO KK
Filing Date
2022-02-28
Publication Date
2026-04-14

AI Technical Summary

Technical Problem

The frequent administration of cells to tissues places a significant burden on the subject, necessitating a medical device that reduces the frequency of such procedures.

Method used

A medical device with a reservoir for storing cell suspension and a clamping portion that fixes near the target site, allowing gradual release of humoral factors produced by cells, with an expandable and contractible structure for continuous administration and replenishment.

Benefits of technology

Reduces the frequency of administration operations by enabling continuous and gradual delivery of humoral factors, alleviating the burden on the subject and allowing replenishment from outside the body.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007845880000001
    Figure 0007845880000001
  • Figure 0007845880000002
    Figure 0007845880000002
Patent Text Reader

Abstract

To provide medical equipment which reduces frequency of administering cells into a tissue.SOLUTION: The medical equipment for administering a liquid containing a liquid factor produced by a tissue to a target region comprises an accumulation part for accumulating a cell suspension and an inserting and holding part for fixing the accumulation part to the vicinity of the target region, the accumulation part having an openable and closable opening.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a medical device for administering a liquid containing a humoral factor produced by cells to a target site.

Background Art

[0002] In recent years, attempts have been made to transplant various cells for the repair of damaged tissues and the like. For example, for the repair of myocardial tissue damaged by ischemic heart diseases such as angina pectoris and myocardial infarction, the use of fetal cardiomyocytes, skeletal myoblasts, mesenchymal stem cells, cardiac stem cells, ES cells, iPS cells, etc. has been attempted (Non-Patent Document 1). As part of such attempts, cell constructs formed using scaffolds and sheet-like cell cultures in which cells are formed into sheets have been developed (Non-Patent Document 2). Another example of the repair of damaged tissues and the like by transplantation of cells and the like is CD34-positive cell therapy for severe lower limb diseases. In such treatment, CD34-positive cells are dissolved in physiological saline and injected intramuscularly at dozens of locations on both feet in a severely ischemic state (Non-Patent Document 3).

[0003] Various attempts have also been made regarding methods and devices for administering cells for transplantation. Patent Document 1 describes a cell retention device capable of retaining cells in a body cavity. Such a device has a device main body that is cylindrical and can be connected to a device delivery portion, and a cell storage portion that is provided in communication with the device main body and consists of a bag capable of storing cells. It is described that a humoral factor released from the cells stored in the bag is allowed to pass through the bag and act on the target site.

[0004] Patent Document 2 describes a cell suspension delivery device. Such a device has a plurality of protrusions for piercing one or more layers of a blood vessel from within the lumen of the blood vessel, and it is described that a cell suspension is delivered to one or more layers of the blood vessel or the tissue around the blood vessel through such protrusions. Patent Document 3 describes a medical system comprising a medical access port and a transport device. In such a system, the medical access port is an implantable access port including a needle consisting of a needle shaft and a removable needle tip, and the system describes extracting fluid from a target through the transport device, the access port body and the needle by the needle penetrating the skin and exiting the body, and introducing fluid or cells into the target through such pathway. [Prior art documents] [Patent Documents]

[0005] [Patent Document 1] Japanese Patent Publication No. 2014-79480 [Patent Document 2] Special Publication No. 2020-500669 [Patent Document 3] Patent No. 6879946

[0006] [Non-Patent Document 1] Haraguchi et al., Stem Cells Transl Med. 2012 Feb;1(2):136-41 [Non-Patent Document 2] Sawa et al., Surg Today. 2012 Jan;42(2):181-4 [Non-Patent Document 3] Fujita et al., Circulation Journal Vol.78, February 2014: 490-501 [Overview of the project] [Problems that the invention aims to solve]

[0007] The inventors of this invention have encountered the problem that when cells are administered into tissue as described above, the administration is often repeated many times, and this frequency of administration places a significant burden on the subject. Therefore, the present invention aims to solve this problem and provide a medical device that can reduce the frequency of cell administration with a simple mechanism. [Means for solving the problem]

[0008] In order to solve the above problems, the inventors diligently conducted research and discovered that the above problems could be solved by gradually releasing cells from a storage area to the target site. Based on this finding, further research led to the completion of the present invention.

[0009] In other words, the present invention relates to the following: [1] A medical device for administering a liquid containing humoral factors produced by cells to a target site, A storage section for storing cell suspension, and Clamping part that fixes the storage part near the target area The medical device comprising a reservoir having a structure that releases a liquid containing humoral factors produced by cells. [2] The medical device according to [1], wherein the clamping portion includes an opening that allows fluid communication with the storage portion, and a liquid containing humoral factors produced by cells released from the storage portion is administered to the target site through the opening. [3] The medical device according to [1] or [2], wherein the storage section further comprises an injection section for injecting a cell suspension. [4] A medical device according to any one of [1] to [3], wherein the reservoir is configured to be expandable and contractible, and when expanded, the reservoir is configured to release a fluid containing humoral factors produced by cells.

[0010] [5] A medical device according to any one of [1] to [4], wherein the injection port is configured to prevent contamination by contaminants. [6] A medical device described in any one of [1] to [5], wherein the target site is a blood vessel. [7] A method of administering a liquid containing a humoral factor produced by cells to a target site, comprising: providing a medical device including a reservoir for storing a cell suspension and a clamping portion for fixing the reservoir near the target site, the reservoir having a structure for releasing a liquid containing a humoral factor produced by cells; exposing the target site; and fixing the clamping portion with the reservoir fixed thereto near the target site. The method as described above. [Advantages of the Invention]

[0011] According to the present invention, since the liquid containing the humoral factor produced by the cells contained in the cell suspension stored in the reservoir fixed near the target site can be continuously administered to the target site gradually, the frequency of administration operations to the subject such as surgery and injection can be reduced, and the burden on the subject can be reduced. Further, according to the present invention, after the cell suspension in the reservoir is reduced by administration, the cell suspension can be replenished from outside the body to the reservoir, so that the frequency of administration operations can be further reduced. [Brief Description of the Drawings]

[0012] [Figure 1] FIG. 1 is a conceptual diagram of a medical device according to a first embodiment of the present invention. [Figure 2] It is a conceptual diagram showing an example of use of the medical device according to the first embodiment of the present invention.

[0013] In one aspect, the present invention relates to a medical device for administering a liquid containing a humoral factor produced by cells to a target site, the medical device including a reservoir for storing a cell suspension and a clamping portion for fixing the reservoir near the target site, the reservoir having a structure for releasing a liquid containing a humoral factor produced by cells.

[0014] In the present invention, the "liquid containing a humoral factor produced by cells" refers to a liquid containing any humoral factor produced by cells contained in a cell suspension. Examples of the liquid containing a humoral factor produced by cells include physiological saline, PBS, medium, etc. containing a humoral factor produced by cells. In the present invention, the liquid containing a humoral factor produced by cells includes a cell suspension. Examples of the humoral factor produced by cells include cell growth factors, differentiation-inducing factors, hematopoietic factors, and various other cytokines. Specifically, examples of the humoral factor include HGF, VEGF, SDF-1, etc.

[0015] In the present invention, the "cell suspension" refers to a state in which cells are suspended in an arbitrary medium. The cells may be in a single cell state, or the cells may be connected to each other via an intervening substance. The cells may contain any gene or a viral vector containing any gene. Further, the cells may be a cell culture. In the present invention, the cell culture refers to what is obtained through a cell culture step, and includes, but is not limited to, spheroids, sheet-like cell cultures, and fragments of sheet-like cell cultures. In the present invention, the medium for suspending cells includes, but is not limited to, water, physiological saline, medium, buffer solution, diluent, cell preservation solution, and swelling bodies such as gels.

[0016] In the present invention, "sheet-like cell culture" refers to a sheet-like structure in which cells are interconnected. The cells may be interconnected directly (including through cellular elements such as adhesion molecules) and / or via intervening substances. The intervening substance is not particularly limited as long as it can connect cells at least physically (mechanically), but examples include extracellular matrix. The intervening substance is preferably cell-derived, in particular, derived from the cells that constitute the cell culture. The cells are connected at least physically (mechanically), but may also be functionally connected, for example, chemically or electrically. The sheet-like cell culture may consist of one cell layer (monolayer) or two or more cell layers (layered (multilayer) structure, for example, two, three, four, five, six layers, etc.). Furthermore, the sheet-like cell culture may have a three-dimensional structure with a thickness exceeding the thickness of a single cell, without the cells exhibiting a clear layered structure. For example, in a vertical cross-section of a sheet-like cell culture, the cells may not be uniformly aligned horizontally, but rather arranged unevenly (for example, in a mosaic pattern).

[0017] The sheet-like cell culture preferably does not contain a scaffold (support). Scaffolds are sometimes used in the art to adhere cells to their surface and / or interior and maintain the physical integrity of the sheet-like cell culture; for example, membranes made of polyvinylidene difluoride (PVDF) are known. However, the sheet-like cell culture of the present invention can maintain its physical integrity even without such a scaffold. Furthermore, the sheet-like cell culture of the present invention preferably consists only of cell-derived materials constituting the sheet-like cell culture and does not contain any other materials.

[0018] In the present invention, "fragments of sheet-like cell culture" refers to a sheet-like cell culture that has been divided into multiple fragments by crushing it. The size of the fragments is not limited to this, but it is preferable that the majority of the fragments are small enough not to enter microvessels and to pass through the inside of an injection needle. Such a size is, for example, an average length of the diagonal of the sheet-shaped plane of 30 μm to 1000 μm, preferably 100 μm to 500 μm. In the present invention, crushing can be carried out by any known method that can obtain fragments of sheet-like cell culture, for example, by suspending a medium containing the sheet-like cell culture using a syringe and needle or pipette.

[0019] The cells included in the cell suspension of the present invention are not particularly limited as long as they produce humoral factors, and examples include adherent cells. Adherent cells include, for example, adherent somatic cells. Examples of somatic cells include myoblasts (e.g., skeletal myoblasts), muscle satellite cells, mesenchymal stem cells (e.g., those derived from bone marrow, adipose tissue, peripheral blood, skin, hair follicles, muscle tissue, endometrium, placenta, umbilical cord blood, etc.), tissue stem cells such as cardiomyocytes, fibroblasts, and cardiac stem cells, embryonic stem cells, pluripotent stem cells such as iPS (induced pluripotent stem) cells, synovial cells, chondrocytes, epithelial cells (e.g., oral mucosal epithelial cells, retinal pigment epithelial cells, nasal mucosal epithelial cells, etc.), endothelial cells (e.g., vascular endothelial cells, etc.), hepatocytes (e.g., hepatocytes, etc.), pancreatic cells (e.g., islet cells, etc.), renal cells, adrenal cells, periodontal ligament cells, gingival cells, periosteal cells, and skin cells. Somatic cells may be those differentiated from iPS cells (iPS cell-derived cells), and examples include iPS cell-derived cardiomyocytes, fibroblasts, myoblasts, epithelial cells, endothelial cells, hepatocytes, pancreatic cells, renal cells, adrenal cells, periodontal ligament cells, gingival cells, periosteal cells, skin cells, synovial cells, and chondrocytes. Cells include suspension cells. Examples of suspension cells include T lymphocytes and B lymphocytes. Preferably, the cells contained in the cell suspension of the present invention are cells capable of promoting angiogenesis, for example, cells capable of secreting angiogenesis-promoting factors, such as cytokines such as VEGF. In such cases, the liquid containing humoral factors produced by the cells is a liquid containing cells capable of promoting angiogenesis, for example, angiogenesis-promoting factors, such as cytokines such as VEGF.

[0020] In the present invention, the "storage section" refers to a section that stores a cell suspension. The storage section of the present invention has a structure that releases a liquid containing humoral factors produced by cells. Examples of materials for the storage section include elastic resin materials. Such elastic resin materials are not limited to polyamides, polyamide elastomers, polyolefins, polyolefin elastomers, polyesters, polyester elastomers, polyurethanes, polyurethane elastomers, polyimides, polyvinyl chlorides, fluororesins, silicone rubbers, latex rubbers, etc., and one or more of these can be used in combination. In another example, a biodegradable polymer can be used as the material for the storage section. Such biodegradable polymers are not limited to polylactic acid, polyglycolic acid, lactic acid-glycolic acid copolymers, polycaprolactone, lactic acid-caprolactone copolymers, glycolic acid-caprolactone copolymers, poly-γ-glutamic acid, etc., and one or more of these can be used in combination. A structure that releases a liquid containing humoral factors produced by cells may, for example, have a reservoir with an opening. The diameter of such an opening is 1 to 500 μm, preferably 10 to 50 μm.

[0021] In one embodiment, the reservoir is configured to be expandable and contractible. The expandable and contractible reservoir is formed, for example, by fusing one end of a tubular elastic resin material (such as silicone) and fixing the other end to a tube or the like. The reservoir can be expanded by delivering a fluid for expansion into the reservoir from such a tube. In this embodiment, the reservoir is not fixed to the clamping part when contracted, but can be fixed to the clamping part by expanding. In this embodiment, the reservoir can be configured as a valve structure that does not release liquid containing humoral factors produced by cells when contracted, but releases liquid containing humoral factors produced by cells when expanded. Furthermore, by providing a valve structure made of a rubber-like material or the like inside the part that releases liquid containing humoral factors produced by cells, it is also possible to create a structure that can release liquid containing humoral factors produced by cells.

[0022] In the present invention, the "clamping portion" refers to a member that fixes the reservoir portion near the target site. The clamping portion has a leg portion on its lower side and an arm portion on its upper side. The leg portion fixes the clamping portion itself near the target site in the tissue, and the arm portion further fixes the reservoir portion to the clamping portion itself. The clamping portion of the present invention is responsible for fixing the reservoir portion and fixing it to the target site on its upper and lower sides, respectively, so that the reservoir portion does not compress or damage the target site, such as a blood vessel, due to changes in shape caused by the expansion or contraction of the reservoir portion. In one embodiment, the leg portion is configured to clamp tissue in the body, preferably a tubular structure in the body such as a blood vessel or lymphatic vessel. The leg portion of the clamping portion may be configured to clamp a blood vessel by force such as a spring, like a clip, or it may be curved to follow the surface of the blood vessel wall and configured to fit the circumferential direction of the blood vessel. The tip of the leg may have a sharp structure, for example, to allow for puncture of surrounding tissue, in order to fix the clamping portion to the surrounding tissue of tubular structures such as blood vessels. The clamping portion of the present invention may have openings. These openings refer to flow paths within the clamping portion and are located on the arm side and on the front or side of the clamping portion. The openings on the arm side allow for fluid communication with the reservoir. Multiple openings may be located on the arm side, allowing for fluid communication with locations that release fluid containing humoral factors produced by multiple cells in the reservoir. The fluid containing humoral factors produced by cells released from the reservoir flows from the arm side opening into the opening and can be administered to the target site through the front or side opening of the clamping portion. Multiple openings may be located on the front or side of the clamping portion. In such cases, the fluid containing humoral factors produced by cells is administered to the target site through multiple openings on the front or side of the opening.

[0023] The medical device of the present invention may further include an injection section. The injection section refers to a component configured to inject a cell suspension into the reservoir. The injection section may be a tubular body that is in fluid communication with the reservoir. For example, if the reservoir is configured to be expandable and contractible, a tube for delivering fluid for expansion, fixed to one end of a tubular elastic resin material, may be used as the injection section. In one embodiment, the injection unit is configured to prevent contamination by contaminants. For example, the injection unit has a lid, and the injection port can be closed with the lid when not injecting a cell suspension.

[0024] In the present invention, the "target site" refers to the site in the target tissue where a fluid containing humoral factors produced by cells is administered. Examples of target sites in tissue include, in living organisms, the site of injury (wound) or its vicinity. Injuries (wounds) are not limited to these, but include vascular injury and stenosis. In such cases, the target site in tissue is in the tissue near the blood vessel, preferably between the blood vessel wall and the surrounding tissue. In one embodiment, the target site in tissue is the vascular sheath surrounding the vascular tissue. In such cases, the clamping portion fixes itself to the blood vessel near the target site and further fixes the reservoir.

[0025] In the present invention, a liquid containing cell-produced humoral factors is administered into the target tissue, preferably into the tissue surrounding the target blood vessels, and more preferably into the tissue surrounding the blood vessels near the lesion site of a patient with a lower limb disease. In one embodiment, the liquid containing cell-produced humoral factors is administered to a patient with peripheral artery disease into the tissue surrounding the blood vessels at a lesion site where blood flow is impaired, for example, in the adductor muscles of the thigh of the lower limb. In this embodiment, the medical device of the present invention can be configured to have an elongated reservoir and be fixed over a long distance along the blood vessels by multiple clamping parts in order to administer the liquid containing cell-produced humoral factors to a wide area of ​​tissue surrounding the blood vessels in the lower limbs. In one embodiment, by administering the liquid containing cell-produced humoral factors into the tissue surrounding the blood vessels near the lesion site, blood flow can be improved by, for example, 35%, 40%, or 45% compared to a healthy state, for example, 7 days after administration. In one embodiment, by administering a fluid containing humoral factors produced by cells into the tissue surrounding blood vessels near the lesion site, blood flow can be improved by, for example, approximately 1.5 times, approximately 2 times, or approximately 2.5 times compared to control saline.

[0026] In one embodiment, the recipient of a liquid containing humoral factors produced by cells using the medical device of the present invention has a disease of the lower limbs. Diseases of the lower limbs include all diseases affecting the lower limbs. Examples of such diseases, but not limited to these, include peripheral artery disease, varicose veins, deep vein thrombosis, and diabetic foot lesions. Preferably, the disease of the lower limbs in the present invention is a disease in which blood vessels in the lower limbs are narrowed or blocked, and blood flow to the lower limbs is impaired, for example, peripheral artery disease. In the present invention, peripheral artery disease includes, but is not limited to, lower limb obstructive arteriosclerosis, Buerger's disease, collagen disease, and in particular severe lower limb obstructive arteriosclerosis is referred to as severe lower limb ischemia. While not bound by any particular theory, the effect of the fluid containing humoral factors produced by cells administered by the medical device of the present invention on lower limb diseases is thought to be due to cytokines such as VEGF contained in the fluid containing humoral factors produced by the administered cells acting directly and / or indirectly on cells in the ischemic area, thereby promoting angiogenesis.

[0027] In another aspect, the present invention relates to a method for administering a liquid containing In the present invention, exposing the target site means, for example, exposing the target site to which a fluid containing humoral factors produced by cells will be administered by making an incision in the body surface. Preferably, the target site is a blood vessel, and the body surface is incised until a portion of the circumferential direction of the blood vessel is exposed.

[0028] The medical device of the present invention can be fixed near the target site after an incision has been made and exposed, and then sutured in a manner that allows the medical device to be implanted in the body. This allows for the continuous administration of a liquid containing humoral factors produced by cells from the medical device to the target site even after suturing. In one embodiment, the medical device provided in the method of the present invention further includes an injection section of a tubular body in fluid communication with a reservoir. In this embodiment, after fixing the medical device of the present invention near the target site, the exposed target site can be sutured closed, leaving only the tip of the injection section outside the body. In this case, the cell suspension in the reservoir can be replenished from outside the body after it has decreased due to the release of fluid containing humoral factors produced by the cells. In this way, the frequency of operations for administering fluid containing humoral factors produced by the cells can be reduced.

[0029] The following describes a preferred embodiment of the present invention: Medical device 1. Figure 1 shows a conceptual diagram of the first embodiment of the present invention. In the figures of this disclosure, the size of each component is exaggerated as appropriate for the sake of clarity, and the illustrated components do not represent their actual size. As shown in Figure 1, the medical device 1 of the present invention includes a storage section 2 for storing a cell suspension and a clamping section 3 for fixing the storage section 2 near the target site. The size of the storage section 2 can be changed according to the size and extent of the target site. Depending on the size of the storage section 2, multiple clamping sections 3 can be used to firmly fix the storage section 2 near the target site. The clamping section 3 has an arm on its upper side and a leg on its lower side, with the arm fixing the storage section 2 and the leg fixing itself near the target site. The storage section 2 has a structure that releases a liquid containing humoral factors produced by cells, allowing the liquid containing humoral factors produced by cells to be released from the storage section 2 to the outside.

[0030] The clamping portion 3 may further have an opening 3a. The opening 3a is in fluid communication with the storage portion 2. The liquid containing humoral factors produced by the cells that exits the storage portion 2 passes through the opening 3a, which allows the administration location and the direction in which the liquid containing humoral factors produced by the cells exits to be changed. As shown in Figure 1, the storage section 2 is connected to an injection section 4, a tubular body that is fluidly connected to the lumen of the storage section 2, and the cell suspension S can be injected into the storage section 2 from the injection port at the tip of the injection section 4. A plate-like body 6 for fixing the injection port can be attached to the tip of the injection section 4, as shown in Figure 1.

[0031] To administer a fluid containing humoral factors produced by cells near a blood vessel using the medical device 1 shown in Figure 1, first, as shown in Figure 2a, an incision is made in the body surface to expose the target blood vessel B. The exposure of the target blood vessel B can be performed in the same manner as the step of harvesting an autologous vein to be used for bypass surgery. At this time, it is not necessary to expose the entire circumferential surface of blood vessel B; it is sufficient to expose only a part of it. Next, as shown in Figure 2b, the clamping part 3, with the constricted reservoir part 2 set in place, is positioned so that the curve of its lower surface clamps onto blood vessel B. The clamping part 3 is fixed to the target site around blood vessel B by inserting its legs at both ends into the surrounding tissue of blood vessel B. Once all the clamping parts 3 (only one is shown in Figure 2) are fixed in the desired position, the cell suspension S is then injected from the injection part 4 into the storage part 2, as shown in Figure 2c, to expand the storage part 2. By expanding, the storage part 2 becomes firmly fixed to the arms of the clamping parts 3. Also, by expanding, the storage part 2 extends a projection toward the opening 3a of the clamping part 3. When the storage part 2 is sufficiently expanded, the tip of the projection opens, and fluid communication is established between the lumen of the storage part 2 and the opening 3a of the clamping part 3, and the fluid containing humoral factors produced by the cells released from the storage part 2 begins to flow into the opening 3a of the clamping part 3.

[0032] When the fluid containing humoral factors produced by the cells begins to be released from the front side of the opening 3a, the incision is sutured, leaving only the tip of the injection section 4 on the body surface, as shown in Figure 2d. At this time, the injection section 4 exposed to the outside of the body surface may be configured to be fixed in a desired position on the body surface by having a plate-shaped fixing device near the tip. As shown in Figure 2e, when the amount of cell suspension S in the storage section 2 inside the body decreases, the cell suspension S in the storage section 2 can be replenished by injecting more cell suspension S from the injection section 4. At this time, the injection section 4 may have a lid 5 to close the injection port into which the cell suspension S is injected, and the lid 5 can prevent dirt, bacteria, etc. from entering the storage section and prevent the cell suspension S in the storage section 3 from leaking out of the body when the cell suspension S is not being injected.

[0033] In other words, the medical device of the present invention can be used sequentially by the following steps. (1) Provide medical device 1. (2) Make an incision on the body surface so that blood vessel B is exposed. (3) A clamping part 3 with a constricted reservoir part 2 set in the vicinity of blood vessel B is placed. (4) The cell suspension S is injected from the injection port 4 into the storage port 2 to expand the storage port 2. (5) Leave only the tip of the injection site 4 outside the body and suture the incision. In the procedure described above, the clamping portion 3 was positioned near blood vessel B before expanding the reservoir portion 2. However, the reservoir portion 2 may be expanded beforehand, and the clamping portion 3 with the expanded reservoir portion 2 set in place may be positioned near blood vessel B. Alternatively, the incision may be sutured while the reservoir portion 2 is in a contracted state, and then the reservoir portion 2 may be expanded by injecting the cell suspension S from outside the body. Furthermore, the reservoir portion 2 may be expanded by injecting any expansion fluid in addition to the cell suspension S.

[0034] As described above, the medical device of the present invention allows for the gradual administration of a liquid containing humoral factors produced by cells in a cell suspension stored in a reservoir fixed near the target site to the target site. This reduces the frequency of administration procedures such as surgery and injections, thereby reducing the burden on the patient. Furthermore, according to the present invention, after the cell suspension in the reservoir decreases due to administration, the cell suspension can be replenished from outside the body, further reducing the frequency of administration procedures. [Explanation of symbols]

[0035] 1. Medical devices 2 Storage section 3 Clamping part 3a opening 4 Injection part 5 Lid 6 Plate-like body S cell suspension B blood vessels

Claims

1. A medical device for administering a liquid containing humoral factors produced by cells to a target site, A storage section for storing cell suspension, and Clamping part that fixes the storage part near the target area It includes a reservoir that has a structure that releases a liquid containing humoral factors produced by cells, The clamping portion is configured to grip tubular structures within the body. The aforementioned medical device.

2. The medical device according to claim 1, wherein the clamping portion includes an opening that allows fluid communication with the storage portion, and the liquid containing humoral factors produced by cells released from the storage portion is administered to the target site through the opening.

3. The medical device according to claim 1 or 2, wherein the storage section further includes an injection section for injecting a cell suspension.

4. The medical device according to any one of claims 1 to 3, wherein the reservoir is configured to be expandable and contractible, and when expanded, the reservoir is configured to release a liquid containing humoral factors produced by cells.

5. The medical device according to any one of claims 1 to 4, wherein the injection section is configured to prevent contamination by contaminants.

6. A medical device according to any one of claims 1 to 5, wherein the target site is a blood vessel.

Citation Information

Patent Citations

  • Cartilage cell container and method of use

    JP2010528712A

  • Cell placement device assembly body, cell placement device, and therapeutic method

    JP2014079480A

  • System for gassing cell implants

    JP2016530980A

  • Two-part implantable therapeutic delivery device

    JP2020500580A

  • Methods and devices for delivery of cell therapy from within the lumen of a blood vessel or from the lumen of an adjacent blood vessel to the intima, subintimal space, media, adventitia, periadventitial space, or perivascular tissue

    JP2020500669A